MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Stock List・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Closed

SectorHealthcare

34.77 2.72

Buy Sell

Overview

Share price change

24h

Current

Min

34.36

Max

35.22

Key metrics
By Trading Economics
Income	-14M -81M
Sales	75K 75K
EPS	-1.22
Profit margin	-108,422.667
Employees	198
EBITDA	-7.8M -81M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+57.74% upside

Dividends
By Dow Jones
Next Earnings	6 May 2026

Market Stats
By TradingEconomics
Market Cap	941M 2.6B
Previous open	32.05
Previous close	34.77

News Sentiment

By Acuity

100%

335 / 348 Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

18.91 / 20.63 Support & Resistance

Celldex Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

17 Apr 2026, 20:26 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 Apr 2026, 18:15 UTC

Major News Events

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 Apr 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 Apr 2026, 16:49 UTC

Major News Events

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 Apr 2026, 22:58 UTC

Earnings

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 Apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 Apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17 Apr 2026, 20:52 UTC

Earnings

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 Apr 2026, 20:50 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 Apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Apr 2026, 20:29 UTC

Earnings

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 Apr 2026, 20:11 UTC

Acquisitions, Mergers, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 Apr 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

17 Apr 2026, 19:34 UTC

Market Talk

Earnings

Acquisitions, Mergers, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 Apr 2026, 19:31 UTC

Market Talk

Major News Events

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 Apr 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17 Apr 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 Apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 Apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 Apr 2026, 18:57 UTC

Major News Events

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 Apr 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 Apr 2026, 18:53 UTC

Acquisitions, Mergers, Takeovers

UCB 2026 Rev Guidance Unchanged

17 Apr 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 Apr 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 Apr 2026, 18:14 UTC

Market Talk

Major News Events

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 Apr 2026, 18:00 UTC

Major News Events

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 Apr 2026, 18:00 UTC

Major News Events

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 Apr 2026, 17:31 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 Apr 2026, 17:26 UTC

Market Talk

Earnings

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Peer Comparison

Price change

Celldex Therapeutics Inc Forecast

Price Target

By TipRanks

57.74% upside

12 Months Forecast

Average 54.5 USD 57.74%

High 90 USD

Low 24 USD

Based on 11 Wall Street analysts offering 12 month price targets forCelldex Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Celldex Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.91 / 20.63Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.